<DOC>
	<DOCNO>NCT00294918</DOCNO>
	<brief_summary>This open-label , multi-center , randomize , parallel-group , maintenance trial Serostim® subject complete prior Serostim® Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome ( HARS ) trial ( Study 22388 ) . The subject , encounter toxicity antecedent protocol , assign 1 milligram ( mg ) dose . All subject randomize 1:1 ratio , receive 2 mg 4 mg Serostim® , begin Day 1 Week 1 . Doses adjust downward subject weigh less 55 kilogram ( kg ) . Serostim® therapy continue assign dos Week 12 ( Period 1 ) . Subjects , encounter toxicity Period 1 , assign 1 mg group Period 2 . All subject randomize 1:1 ratio receive 2 mg 1 mg Serostim® weight adjust basis . Period 2 therapy begin Day 1 Week 13 , continue Week 36 . Study visit require Screening ( , Final Visit antecedent trial ) , Day 1 Week 1 ( Baseline ) , Weeks 2 , 6 , 12 , 14 , 24 , 30 36 .</brief_summary>
	<brief_title>An Efficacy Safety Trial Serostim® Maintenance Treatment Effect Obtained During Study Serostim® Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Complete treatment prescribe antecedent protocol ( Study 22388 ) Be able willing comply protocol duration study , include concomitant therapy restriction Have give write informed consent If female , postmenopausal , surgically sterile , use adequate contraception Experienced protocol define toxicity adverse event , cause premature withdrawal antecedent study ( Study 22388 ) Withdrew antecedent study discontinue prematurely reason Based Final Visit evaluation antecedent trial , would require withdraw antecedent protocol , ( theoretically ) antecedent trial continue beyond Final Visit Based Final Visit evaluation antecedent trial , would require temporarily stop reduce dose study drug , ( theoretically ) antecedent trial continue beyond Final Visit . This apply subject whose study drug temporarily stop whose study drug dose reduce prior Final Visit ( Screening ) , provide continued antecedent protocol stable time Final Visit ( Screening )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome ( HARS )</keyword>
	<keyword>Human Immunodeficiency Virus Infections</keyword>
	<keyword>Serostim®</keyword>
	<keyword>recombinant human growth hormone ( r-hGH )</keyword>
</DOC>